New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Alto Neuroscience, Inc. (ANRO) vs Nektar Therapeutics (NKTR)
- Alto Neuroscience, Inc. ANRO 25.37 −4.30%
- Nektar Therapeutics NKTR 30.20 −7.19%
Alto Neuroscience, Inc. and Nektar Therapeutics are both Biotechnology companies. Alto Neuroscience, Inc. and Nektar Therapeutics are of similar size ($1.1B and $1.1B). Across the 10 metrics below, Alto Neuroscience, Inc. leads on 5 and Nektar Therapeutics on 5.
Valuation
Profitability
| Metric | ANRO | NKTR | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 100.00% | 70.18% |
| Operating margin | — | (319.75%) | 0.00% |
| Net margin | — | (339.67%) | 0.00% |
| Free cash flow margin | — | (493.41%) | 0.00% |
| Return on equity | (46.65%) | (37.92%) | (51.58%) |
| Return on assets | (40.20%) | (26.48%) | (45.91%) |
| Return on invested capital | 0.00% | (44.31%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack